Across cancers, RSPO2 amplifications exhibited the worst outcomes in both disease-free and progression-free survival (HR: 1.58 and 1.21, p-value: 0.0003 and 0.0105 CI: 0.799–2.361 and 0.849–1.571, respectively) (Figure 2A). Here, RSPO2 is linked to cancer.